# Efficacy and Tolerability of Topical LFX453 for External Genital Warts

> **NCT02482428** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 88 (actual)

## Conditions studied

- External Genital Warts

## Interventions

- **DRUG:** Investigational Treatment
- **DRUG:** Aldara

## Key facts

- **NCT ID:** NCT02482428
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-12
- **Primary completion:** 2016-05-31
- **Final completion:** 2016-05-31
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02482428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02482428, "Efficacy and Tolerability of Topical LFX453 for External Genital Warts". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02482428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*